NorthStar Medical Radioisotopes Marks Critical Milestone in Readiness for Clinical Batch Production
NorthStar Appoints Peter Pfreundschuh to Board of Managers
NorthStar Medical Radioisotopes, LLC, a global provider of radiopharmaceuticals used to detect and treat cancer and other serious diseases, has signed a Clinical Supply Agreement with Clarity Pharmaceuticals for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials. The overarching Master Service agreement and associated Clinical Supply Agreement are effective immediately and the initial production of supply to support Clarity trials is expected to occur before the end of 2024.
NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement to Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials
NorthStar Medical Radioisotopes Announces Participation in Upcoming 2024 Jefferies Radiopharma Innovation Summit
NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers
NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Agreement
NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration
NorthStar Announces Participation in 2023 Truist Securities Biopharma Symposium
BELOIT, Wis. & CHESTER SPRINGS, Pa.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. (Curadh), a global MTR focused clinical, research and advisory organization, today announced the signing of a strategic long term supply agreement for the therapeutic radioisotope non-carrier added (n.c.a.) actinium-225 (Ac-225).